ArticlePolymers2019
3D Bioprinting of Novel Biocompatible Scaffolds for Endothelial Cell Repair.
Article in Polymers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- 3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.Frontiers in bioengineering and biotechnology · 2025Review
- Sustained dual delivery of metronidazole and viable Lactobacillus crispatus from 3D-printed silicone shells.Biomaterials advances · 2024Article
- Reasoning on Pore Terminology in 3D Bioprinting.Gels (Basel, Switzerland) · 2024Review
- Polydopamine Blending Increases Human Cell Proliferation in Gelatin-Xanthan Gum 3D-Printed Hydrogel.Gels (Basel, Switzerland) · 2024Article
- Advances in 3D bioprinting for regenerative medicine applications.Regenerative biomaterials · 2024Review
- Biomaterials / bioinks and extrusion bioprinting.Bioactive materials · 2023Review
- Nanocomposite Bioprinting for Tissue Engineering Applications.Gels (Basel, Switzerland) · 2023Review
- 1Biomaterial inks for extrusion-based 3D bioprinting: Property, classification, modification, and selection.International journal of bioprinting · 2023Article
- 3D Printing in Regenerative Medicine: Technologies and Resources Utilized.International journal of molecular sciences · 2022Review
- Smart Bioinks for the Printing of Human Tissue Models.Biomolecules · 2022Review
- 3D Bioprinting of Gelatin-Xanthan Gum Composite Hydrogels for Growth of Human Skin Cells.International journal of molecular sciences · 2022Article
- Design and characterization of 3D printed, neomycin-eluting poly-L-lactide mats for wound-healing applications.Journal of materials science. Materials in medicine · 2021Article
- A Review of Vat Photopolymerization Technology: Materials, Applications, Challenges, and Future Trends of 3D Printing.Polymers · 2021Review
- Exploration of Bioengineered Scaffolds Composed of Thermo-Responsive Polymers for Drug Delivery in Wound Healing.International journal of molecular sciences · 2021Review
- Review
- 3D Printed Calcium Phosphate Cement (CPC) Scaffolds for Anti-Cancer Drug Delivery.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to develop and evaluate an optimized 3D bioprinting technology in order to fabricate novel scaffolds for the application of endothelial cell repair. Various biocompatible and biodegradable macroporous scaffolds (D = 10 mm) with interconnected pores (D = ~500 µm) were fabricated using a commercially available 3D bioprinter (r3bEL mini, SE3D, USA). The resolution of the printing layers was set at ~100 µm for all scaffolds. Various compositions of polylactic acid (PLA), polyethylene glycol (PEG) and pluronic F127 (F127) formulations were prepared and optimized to develop semi-solid viscous bioinks. Either dimethyloxalylglycine (DMOG) or erythroprotein (EPO) was used as a model drug and loaded in the viscous biocompatible ink formulations with a final concentration of 30% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.